Search
Cancer Clinical Trials in Baton Rouge, LA
A listing of 64 Cancer clinical trials in Baton Rouge, LA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 64 of 64
The city of Baton Rouge, Louisiana, currently has 64 active clinical trials seeking participants for Cancer research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Join a clinical trial today and take a step toward finding a better solution for you. Earn money for your time and no-cost medical treatment is provided.
Featured Trial
COPD Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Featured Trial
Child/Teen Migraine Study
Recruiting
Sign up for a clinical trial today and contribute to the advancement of medical research, paving the way for innovative treatments. Receive financial compensation for your participation and benefit from complimentary medical care.
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Recruiting
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts:
Cohort A: CRC
Cohort B: Gastric and GEJ cancer
Cohort C: TNBC
Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Hematology Oncology Clinic, Baton Rouge, Louisiana
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Medical Center of Baton Rouge, Baton Rouge, Louisiana +1 locations
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Recruiting
This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2022
Locations: Hematology Oncology Clinic Baton Rouge / Sarah Cannon, Baton Rouge, Louisiana
Conditions: Gastric Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: Hematology Oncology Clinic, Baton Rouge, Louisiana
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
61 - 64 of 64